Gilead to Withdraw US Indication for Sacituzumab Govitecan in Metastatic Urothelial Cancer
Gilead will voluntarily withdraw the United States indication for sacituzumab govitecan in metastatic urothelial cancer.
Gilead will voluntarily withdraw the United States indication for sacituzumab govitecan in metastatic urothelial cancer.
Hear the latest research about what may be contributing to the alarming trend of young people getting cancer earlier in their lives than previous generations.
Data from the phase 3 SPOTLIGHT trial and the phase 3 GLOW trial supported the approval of zolbetuximab plus chemotherapy in this indication.
Anil Parwani, MD, PhD, discusses how he sees artificial intelligence technology contributing to personalized medicine and helping to tailor treatment plans for individual patients in…
Key PointsIn the A.R.R.O.W.2 study, ORR was comparable between once-weekly KRd56 and twice-weekly KRd27 but not significant for noninferiority.With numeric
On October 18, 2024, the FDA approved zolbetuximab-clzb (Vyloy, Astellas Pharma US, Inc.) with fluoropyrimidine- and platinum-containing chemotherapy for gastric or gastroesophageal junction adenocarcinoma.
The role of B cells in cancer remains incompletely understood. Three recent publications, including a study by Fitzsimons et al. in this issue of Cancer Cell,…
The Atlas of Inspiring Hispanic/Latinx Scientists is a grassroots effort developed to showcase the expertise, talents, and diversity of Hispanic and Latinx scientific faculty.
The FDA approved zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.
The FDA approved zolbetuximab-clzb plus fluoropyrimidine- and platinum-containing chemotherapy for patients with CLDN18.2-positive locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
On October 18, 2024, the FDA approved zolbetuximab-clzb (Vyloy, Astellas Pharma US, Inc.) with fluoropyrimidine- and platinum-containing chemotherapy for gastric or gastroesophageal junction adenocarcinoma.